In the context of warfarin therapy, characterized by its narrow therapeutic index and dependence on vitamin K-dependent clotting factor synthesis inhibition, what is the correct course of action when potential CYP inducers or inhibitors are introduced?*1 pointA) Increasing the dose of warfarin is necessary when potential CYP inducers are introduced.B) Warfarin's therapeutic index widens when potential CYP inhibitors are introduced.C) Frequent INR measurements is required for adequate monitoring in the presence of CYP inducersD) Achieving a therapeutic level of warfarin is a rapid process, typically occurring within a day.E) Heparin is contraindicated when potential CYP inducers are introduced.F) Stable INR levels indicate that the patient does not require additional monitoring in the presence of potential CYP inducers or inhibitors.
Question
In the context of warfarin therapy, characterized by its narrow therapeutic index and dependence on vitamin K-dependent clotting factor synthesis inhibition, what is the correct course of action when potential CYP inducers or inhibitors are introduced?*1 pointA) Increasing the dose of warfarin is necessary when potential CYP inducers are introduced.B) Warfarin's therapeutic index widens when potential CYP inhibitors are introduced.C) Frequent INR measurements is required for adequate monitoring in the presence of CYP inducersD) Achieving a therapeutic level of warfarin is a rapid process, typically occurring within a day.E) Heparin is contraindicated when potential CYP inducers are introduced.F) Stable INR levels indicate that the patient does not require additional monitoring in the presence of potential CYP inducers or inhibitors.
Solution
The correct course of action when potential CYP inducers or inhibitors are introduced in the context of warfarin therapy is C) Frequent INR measurements is required for adequate monitoring in the presence of CYP inducers.
Warfarin is a medication that works by inhibiting the synthesis of vitamin K-dependent clotting factors. Its therapeutic index is narrow, meaning there's a small difference between a therapeutic and toxic dose.
When potential CYP inducers are introduced, they can increase the metabolism of warfarin, potentially decreasing its effectiveness. Therefore, it's important to frequently measure the patient's International Normalized Ratio (INR), which is a measure of blood clotting, to ensure that the patient is still in the therapeutic range.
On the other hand, potential CYP inhibitors can decrease the metabolism of warfarin, potentially leading to an overdose. Again, frequent INR measurements are necessary to monitor the patient's response to the medication.
The other options are incorrect. Increasing the dose of warfarin when potential CYP inducers are introduced (A) could lead to an overdose if the inducer is discontinued. Warfarin's therapeutic index does not widen when potential CYP inhibitors are introduced (B). Achieving a therapeutic level of warfarin is not a rapid process, typically occurring within a day (D). Heparin is not contraindicated when potential CYP inducers are introduced (E). Stable INR levels do not indicate that the patient does not require additional monitoring in the presence of potential CYP inducers or inhibitors (F).
Similar Questions
The anticoagulant warfarin acts by blocking the enzyme that activates vitamin K. Question 5 options: True False
The nurse is preparing to administer medications to assigned clients. Which prescription should the nurse clarify with the primary healthcare provider (PHCP)?A. Warfarin to a client with an international normalized ratio (INR) of 1.8 seconds [0.9–1.2]B. Digoxin to a client with a serum potassium level of 3.1 mEq/L [3.5-5 mEq/L, mmol/L]C. Enoxaparin to a client with a platelet count of 155,000 mm3 [150-400 mm3, 130–380 × 10⁹/L]D. Lisinopril to a client with a serum creatinine level of 0.6 mg/dL [Male: 0.6-1.2 mg/dL, Female: 0.5-1.1 mg/dL, Female 30–190 IU/L, Male 30–250 IU/L]
Genotypes of one pair of the following genes could benefit patients treated with warfarin.Question 9Answera.CYP2C9 and CYP2B1b.CYP2C19*2 and CYP2C9*3c.HLA-B∗1502 and CYP2D6d.CYP2C9 and VKORC1
Jasmin's dad has just had a stroke and been put on Warfarin. Which of the following statements about warfarin is true?Group of answer choicesWarfarin helps with blood clotting Warfarin levels in the blood are monitored if a doctor suspects that levels are be high or the patient is non compliant Warfarin should not be taken with foods containing Vitamin K Warfarin is a "blood thinner"
The presence of a compound called ______ inhibits adherence of platelets to endothelial cells lining blood vessel walls.Multiple choice question.antithrombinprostacyclinheparin
Upgrade your grade with Knowee
Get personalized homework help. Review tough concepts in more detail, or go deeper into your topic by exploring other relevant questions.